Vaxcyte, Inc. Executive Severance Agreements Amendment

Vaxcyte, Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including the CEO, President, CFO, COO, and Chief Technical Operations Officer. These amendments, approved by the Compensation Committee and effective December 31, 2025, aim to align severance components with peer group levels. Key changes include increased severance multipliers for base salary and bonuses in cases of Qualifying Termination and CIC Qualifying Termination. For the CEO, the base salary severance multiplier increases from 1.0x to 1.5x, and the CIC base salary severance multiplier increases from 1.5x to 2.0x. For other listed executives, the base salary severance multiplier increases from 0.75x or 0.5x to 1.0x, and the CIC base salary severance multiplier increases from 1.0x or 0.75x to 1.5x. The amendments also adjust COBRA severance multipliers.